1 result for "NovoMab BioPharmaceuticals Inc"
Add this URL to any RSS reader. Updated daily.
NovoMab BioPharmaceuticals Inc CTLA-4 Antibody Patent US12606624B2
The USPTO granted Patent US12606624B2 to NovoMab BioPharmaceuticals Inc covering an antibody that specifically binds to human CTLA-4. The patent discloses three complementarity-determining regions (CDR1-3) and applications in medicaments and kits for potential tumor growth inhibition. The patent application (18456503) was filed on August 27, 2023.
Routine
Rule
Intellectual Property
Get alerts for "NovoMab BioPharmaceuticals Inc"
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Browse Categories
Agriculture & Food Safety
73
AI Regulation
3
Banking & Finance
414
Consumer Protection
89
Courts & Legal
411
Data Privacy & Cybersecurity
90
Defense & National Security
53
Education
55
Energy
100
Environment
152
Gaming
2
Government & Legislation
431
Healthcare
15
Healthcare & Life Sciences
375
Immigration
10
Insurance
76
Labor & Employment
138
Pharma & Drug Safety
21
Professional Licensing
8
Real Estate & Housing
78
Securities & Markets
154
Tax
78
Telecom & Technology
47
Trade & Sanctions
141
Transportation
91
Get alerts for "NovoMab BioPharmaceuticals Inc"
We'll email you when new changes match "NovoMab BioPharmaceuticals Inc".
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.
You're subscribed!